Compare EBMT & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EBMT | NRXP |
|---|---|---|
| Founded | 1922 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.7M | 151.1M |
| IPO Year | 2009 | 2017 |
| Metric | EBMT | NRXP |
|---|---|---|
| Price | $20.73 | $2.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $24.00 | ★ $38.50 |
| AVG Volume (30 Days) | 19.8K | ★ 590.6K |
| Earning Date | 10-27-2026 | 11-16-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | 53.23 | ★ 69.70 |
| EPS | ★ 0.98 | N/A |
| Revenue | N/A | ★ $1,225,000.00 |
| Revenue This Year | $5.89 | $357.94 |
| Revenue Next Year | $3.84 | $1,507.30 |
| P/E Ratio | $21.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.80 | $1.65 |
| 52 Week High | $24.66 | $5.06 |
| Indicator | EBMT | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 29.47 | 32.64 |
| Support Level | $20.00 | $2.81 |
| Resistance Level | $22.63 | $3.62 |
| Average True Range (ATR) | 0.56 | 0.13 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 17.02 | 7.08 |
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.